title: Effect of priming with carrier on response to conjugate vaccine.
abstract: To examine whether prior immunity against a carrier protein modulates the serological response to injected peptide haptens attached to the same carrier in man, baseline tetanus antitoxin levels in volunteers who received a malaria sporozoite peptide-tetanus toxoid conjugate vaccine were compared with post-vaccination IgM and IgG antibody titres against the sporozoite antigen. In tetanus-vaccinated North American recipients of low doses of conjugate vaccine there were significant dose-dependent negative correlations between these variables, which suggests that epitopic suppression may occur in man. In contrast, Venezuelans living in non-malarious areas and mostly naive to tetanus toxoid showed a notable IgM response to the sporozoite antigen. The findings indicate that epitopic suppression and immune enhancement occur in man, and that the specific immunological responses to conjugate peptide vaccines may be difficult to predict.
authors: Division of Geographic Medicine, University of Maryland School of Medicine, Baltimore.
authors: D
authors: D
authors: Di John
authors: S S
authors: SS
authors: Wasserman
authors: J R
authors: JR
authors: Torres
authors: M J
authors: MJ
authors: Cortesia
authors: J
authors: J
authors: Murillo
authors: G A
authors: GA
authors: Losonsky
authors: D A
authors: DA
authors: Herrington
authors: D
authors: D
authors: Stürcher
authors: M M
authors: MM
authors: Levine
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000293:Adolescent; D000328:Adult; D000368:Aged; D000818:Animals; D000913:Antibodies, Protozoan / Q000032:analysis; D002352:Carrier Proteins / Q000276:immunology*; D000939:Epitopes / Q000032:analysis; D005260:Female; D006241:Haptens / Q000276:immunology; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis; D007075:Immunoglobulin M / Q000032:analysis; D008288:Malaria / Q000097:blood / Q000276:immunology* / Q000517:prevention & control; D008297:Male; D008396:Maryland; D008875:Middle Aged; D009842:Oligopeptides / Q000276:immunology*; D010961:Plasmodium / Q000276:immunology; D013742:Tetanus / Q000097:blood / Q000276:immunology* / Q000517:prevention & control; D013743:Tetanus Antitoxin / Q000032:analysis; D013745:Tetanus Toxoid / Q000276:immunology*; D013997:Time Factors; D014612:Vaccines / Q000276:immunology*; D014614:Vaccines, Synthetic / Q000276:immunology*; D014687:Venezuela
chemical_list: D000276:Adjuvants, Immunologic; D000913:Antibodies, Protozoan; D002352:Carrier Proteins; D000939:Epitopes; D006241:Haptens; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D009842:Oligopeptides; D013743:Tetanus Antitoxin; D013745:Tetanus Toxoid; D014612:Vaccines; D014614:Vaccines, Synthetic; C052953:(asparaginyl-alanyl-asparaginyl-proline)3